Trial Profile

Targeted Treatment Based on CtDNA Genotyping Combined with Tislelizumab and HAIC As Salvage Treatment for Advanced Colorectal Cancer Liver Metastasis Failed from Standard Systemic Treatment (SALVLIV Trial)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Fruquintinib (Primary) ; Tislelizumab (Primary) ; Fluorouracil; Irinotecan; Oxaliplatin
Indications Colorectal cancer
Focus Therapeutic Use
Acronyms SALVLIV Trial

24 Jan 2024 Status changed from not yet recruiting to recruiting.
24 Jan 2024 Planned End Date changed from 28 Jan 2027 to 23 Jan 2027.
24 Jan 2024 Planned primary completion date changed from 22 Jan 2026 to 23 Jan 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com